Health and FitnessHealth and Fitness
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
Bradesco-Investorentag 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
MTS Declares Quarterly Dividend
[ Tue, Nov 22nd 2011 ] - Market Wire
QNB Corp. Declares Dividend
[ Tue, Nov 22nd 2011 ] - Market Wire
Bradesco Investor Day 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
ComEd Ready for Winter's Wrath

NuPathe to Present at the Piper Jaffray 23rd Annual Healthcare Conference


Published on 2011-11-22 10:41:05 - Market Wire
  Print publication without navigation


November 22, 2011 13:30 ET

NuPathe to Present at the Piper Jaffray 23rd Annual Healthcare Conference

CONSHOHOCKEN, PA--(Marketwire - Nov 22, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that [ Jane Hollingsworth ], chief executive officer, will present a company overview at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, 2011, at 4:00 p.m. EST. The conference is being held at The New York Palace Hotel in New York, NY.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the presentation.

About NuPathe
NuPathe Inc. ([ www.nupathe.com ]) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.